Clayton Beard, Ph.D.

Vice President, Therapeutic Discovery


Clayton is leading our Discovery Research efforts to evaluate ARCUS nucleases in cell culture and in relevant disease models. Clayton came to Precision from Novartis Vaccines where he was Head of the Viral Vectors Lab and later led Technical Development teams for Virology, Cell line, and High throughput analytics. Prior to Novartis, he was VP of Research at Global Vaccines Inc., which was a non-profit vaccine company that he helped spin out of the University of North Carolina. Clayton previously led a molecular evolution team at Maxygen Inc., developing improved vaccine antigens for viral diseases. He received his Ph.D. in molecular virology from the University of Georgia Genetics Department and went on to complete postdoctoral work at Plum Island Animal Disease Center studying DNA vaccines for BSL-3 viruses. When Clayton is not at Precision, he enjoys spending time with his kids or, as a certified gearhead, working on several vintage cars that he (usually) keeps running.

Back